Aragen Prepares to Launch GMP Biologics Production in Bangalore by Late July

• Aragen’s Bangalore facility has completed qualification and will begin GMP manufacturing in late July 2025.

• The site features intensified fed batch production with >25 g/L titers and flexible bioreactor configurations.

Aragen, a global contract research, development and manufacturing organisation (CRDMO), has announced that its biologics manufacturing facility in Bangalore, India has completed facility and equipment qualification. The site is set to begin GMP production in late July 2025.

The facility houses multiple 2,000-litre single-use bioreactors designed for fed batch and intensified fed batch production. These feed into a shared downstream purification suite, allowing the flexibility to manage multiple client programmes in parallel or scale up to commercial quantities. The platform has demonstrated productivity exceeding 25 g/L.

Subodh Deshmukh, CEO, Biologics and President, Development, commented, “Our first customer program will progress to GMP production as early as late July this year.”

The Bangalore site complements Aragen’s existing biologics capabilities in Morgan Hill, California, which supports non-GMP manufacturing at early stages. Together, the two sites offer integrated services from cell line development to commercial-scale production of monoclonal antibodies, biosimilars, and other recombinant proteins.